Tvardi Therapeutics, Inc. (TVRD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Tvardi Therapeutics, Inc. stock (TVRD) is currently trading at $3.29. Analyst consensus price target for TVRD is $8.67. WallStSmart rates TVRD as Sell.
- TVRD PE ratio analysis and historical PE chart
- TVRD PS ratio (Price-to-Sales) history and trend
- TVRD intrinsic value — DCF, Graham Number, EPV models
- TVRD stock price prediction 2025 2026 2027 2028 2029 2030
- TVRD fair value vs current price
- TVRD insider transactions and insider buying
- Is TVRD undervalued or overvalued?
- Tvardi Therapeutics, Inc. financial analysis — revenue, earnings, cash flow
- TVRD Piotroski F-Score and Altman Z-Score
- TVRD analyst price target and Smart Rating
Tvardi Therapeutics, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Tvardi Therapeutics, Inc. (TVRD) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Tvardi Therapeutics, Inc. (TVRD) Key Strengths (1)
Trading at 1.13x book value, attractively priced
Supporting Valuation Data
Tvardi Therapeutics, Inc. (TVRD) Areas to Watch (3)
Company is destroying shareholder value
Micro-cap company with very limited liquidity and high volatility
Moderate institutional interest at 30.17%
Tvardi Therapeutics, Inc. (TVRD) Detailed Analysis Report
Overall Assessment
This company scores 17/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 8.0/10) while 3 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.13) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Market Cap, Institutional Own.. Profitability pressure is visible in Return on Equity at -135.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -135.60% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TVRD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TVRD's Price-to-Sales ratio of 5.32x sits near its historical average of 5.45x (79th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 89% below its historical high of 47.74x set in Sep 2025, and 4336% above its historical low of 0.12x in Jun 2024. Over the past 12 months, the PS ratio has compressed from ~6.8x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Tvardi Therapeutics, Inc. (TVRD) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Tvardi Therapeutics, Inc. operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.01 indicates a conservative balance sheet with 21M in cash.
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Tvardi Therapeutics, Inc..
Bottom Line
Tvardi Therapeutics, Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Tvardi Therapeutics, Inc.(TVRD)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering innovative therapies for oncology and other critical medical challenges. Utilizing its proprietary drug discovery platform, Tvardi focuses on the development of small molecule therapies that target protein degradation pathways to offer therapeutic advantages in cancer treatment. Its lead candidate, TVB-2640, is designed to undermine cancer cell survival mechanisms, showcasing the company's dedication to advancing treatment options for patients facing malignancies. With a strong pipeline and a commitment to scientific excellence, Tvardi is well-positioned to transform the cancer therapeutics arena and improve patient outcomes.